Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KSF IgG IL-9
- Development stage
- Preclinical
- Lead developer
- Philogen
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
KSF IgG IL-9 is a non-targeted control immunocytokine used in preclinical research to evaluate the efficacy of interleukin-9 (IL-9) delivery. It comprises the KSF monoclonal antibody, which is specific for hen egg lysozyme (an antigen absent in mammalian tissues), in a full-length IgG format fused to IL-9. Developed by Philogen, it serves as a negative control for targeted immunocytokines like F8-IL-9, which targets the extra-domain A (EDA) of fibronectin. Research using this construct has focused on pulmonary hypertension, where IL-9 delivery is investigated for its potential to modulate pulmonary vascular remodeling and inflammation. By comparing the non-targeted KSF format with targeted formats, researchers can determine the necessity of antibody-mediated localization for therapeutic effect.
- Other names
- KSF-IL-9KSF-IL9KSF-IL 9KSF-IgG-Interleukin-9KSF-IgG-Interleukin9KSF-IgG-Interleukin 9
02
Targets
IL9R (Interleukin-9 receptor)
Beyond the preview
Go deeper on KSF IgG IL-9.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KSF IgG IL-9.